CNR1 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

GO_0007584Biological processresponse to nutrient
GO_0031999Biological processnegative regulation of fatty acid beta-oxidation
GO_0050796Biological processregulation of insulin secretion
GO_0033602Biological processnegative regulation of dopamine secretion
GO_0007283Biological processspermatogenesis
GO_0007188Biological processadenylate cyclase-modulating G protein-coupled receptor signaling pathway
GO_0098921Biological processretrograde trans-synaptic signaling by endocannabinoid
GO_0031622Biological processpositive regulation of fever generation
GO_0045777Biological processpositive regulation of blood pressure
GO_0010976Biological processpositive regulation of neuron projection development
GO_0038171Biological processcannabinoid signaling pathway
GO_0060259Biological processregulation of feeding behavior
GO_0099553Biological processtrans-synaptic signaling by endocannabinoid, modulating synaptic transmission
GO_0002866Biological processpositive regulation of acute inflammatory response to antigenic stimulus
GO_0032496Biological processresponse to lipopolysaccharide
GO_0051966Biological processregulation of synaptic transmission, glutamatergic
GO_0045471Biological processresponse to ethanol
GO_0060405Biological processregulation of penile erection
GO_0007413Biological processaxonal fasciculation
GO_0042220Biological processresponse to cocaine
GO_0045776Biological processnegative regulation of blood pressure
GO_0045759Biological processnegative regulation of action potential
GO_0035094Biological processresponse to nicotine
GO_0099509Biological processregulation of presynaptic cytosolic calcium ion concentration
GO_0007189Biological processadenylate cyclase-activating G protein-coupled receptor signaling pathway
GO_0007187Biological processG protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO_0007613Biological processmemory
GO_0014063Biological processnegative regulation of serotonin secretion
GO_0043065Biological processpositive regulation of apoptotic process
GO_0033004Biological processnegative regulation of mast cell activation
GO_0019222Biological processregulation of metabolic process
GO_0042593Biological processglucose homeostasis
GO_0060135Biological processmaternal process involved in female pregnancy
GO_0032228Biological processregulation of synaptic transmission, GABAergic
GO_0098978Cellular componentglutamatergic synapse
GO_0005886Cellular componentplasma membrane
GO_0045121Cellular componentmembrane raft
GO_0042734Cellular componentpresynaptic membrane
GO_0098982Cellular componentGABA-ergic synapse
GO_0015629Cellular componentactin cytoskeleton
GO_0030426Cellular componentgrowth cone
GO_0005737Cellular componentcytoplasm
GO_0005741Cellular componentmitochondrial outer membrane
GO_0004930Molecular functionG protein-coupled receptor activity
GO_0042802Molecular functionidentical protein binding
GO_0005515Molecular functionprotein binding
GO_0004949Molecular functioncannabinoid receptor activity

IV. Literature review

[source]
Gene nameCNR1
Protein nameCannabinoid receptor 1
Cannabinoid receptor 1 (CB-R) (CB1) (CANN6)
SynonymsCNR
DescriptionFUNCTION: G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC) . Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP . In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses. At high doses, CNR1 signal transduction involves G-protein alpha-i protein activation and subsequent inhibition of mitochondrial soluble adenylate cyclase, decrease in cyclic AMP concentration, inhibition of protein kinase A (PKA)-dependent phosphorylation of specific subunits of the mitochondrial electron transport system, including NDUFS2. In the hypothalamus, inhibits leptin-induced reactive oxygen species (ROS) formation and mediates cannabinoid-induced increase in SREBF1 and FASN gene expression. In response to cannabinoids, drives the release of orexigenic beta-endorphin, but not that of melanocyte-stimulating hormone alpha/alpha-MSH, from hypothalamic POMC neurons, hence promoting food intake. In the hippocampus, regulates cellular respiration and energy production in response to cannabinoids. Involved in cannabinoid-dependent depolarization-induced suppression of inhibition (DSI), a process in which depolarization of CA1 postsynaptic pyramidal neurons mobilizes eCBs, which retrogradely activate presynaptic CB1 receptors, transiently decreasing GABAergic inhibitory neurotransmission. Also reduces excitatory synaptic transmission (By similarity). In superior cervical ganglions and cerebral vascular smooth muscle cells, inhibits voltage-gated Ca(2+) channels in a constitutive, as well as agonist-dependent manner . In cerebral vascular smooth muscle cells, cannabinoid-induced inhibition of voltage-gated Ca(2+) channels leads to vasodilation and decreased vascular tone (By similarity). Induces leptin production in adipocytes and reduces LRP2-mediated leptin clearance in the kidney, hence participating in hyperleptinemia. In adipose tissue, CNR1 signaling leads to increased expression of SREBF1, ACACA and FASN genes (By similarity). In the liver, activation by endocannabinoids leads to increased de novo lipogenesis and reduced fatty acid catabolism, associated with increased expression of SREBF1/SREBP-1, GCK, ACACA, ACACB and FASN genes. May also affect de novo cholesterol synthesis and HDL-cholesteryl ether uptake. Peripherally modulates energy metabolism (By similarity). In high carbohydrate diet-induced obesity, may decrease the expression of mitochondrial dihydrolipoyl dehydrogenase/DLD in striated muscles, as well as that of selected glucose/ pyruvate metabolic enzymes, hence affecting energy expenditure through mitochondrial metabolism (By similarity). In response to cannabinoid anandamide, elicits a pro-inflammatory response in macrophages, which involves NLRP3 inflammasome activation and IL1B and IL18 secretion (By similarity). In macrophages infiltrating pancreatic islets, this process may participate in the progression of type-2 diabetes and associated loss of pancreatic beta-cells . .; FUNCTION: [Isoform 1]: Binds both 2-arachidonoylglycerol (2-AG) and anandamide. .; FUNCTION: [Isoform 2]: Only binds 2-arachidonoylglycerol (2-AG) with high affinity. Contrary to its effect on isoform 1, 2-AG behaves as an inverse agonist on isoform 2 in assays measuring GTP binding to membranes. .; FUNCTION: [Isoform 3]: Only binds 2-arachidonoylglycerol (2-AG) with high affinity. Contrary to its effect on isoform 1, 2-AG behaves as an inverse agonist on isoform 3 in assays measuring GTP binding to membranes. .

FUNCTION: G-protein coupled receptor for cannabinoids, including endocannabinoids (eCBs), such as N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG). Signaling typically involves reduction in cyclic AMP. .

FUNCTION: G-protein coupled receptor for cannabinoids, including endocannabinoids (eCBs), such as N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG). Signaling typically involves reduction in cyclic AMP. .

AccessionsF8W908
P21554
ENST00000468898.2 [P21554-3]
Q9BYY6
V5KA96
ENST00000428600.3 [P21554-1]
S5TLS4
F8W187
ENST00000369501.3 [P21554-1]
ENST00000549890.2 [P21554-1]
ENST00000551417
ENST00000369499.3 [P21554-1]
ENST00000362094.6
ENST00000551417.2 [P21554-1]